REDHILL BIOPHARMA LTD. (RDHL) Financial Statements
REDHILL BIOPHARMA LTD. (RDHL) files with the U.S. Securities and Exchange Commission under CIK 0001553846. 10KGenie shows its annual statements from SEC filings.
Key Figures, Fiscal Year 2025
- Revenue
- $286.00 thousand
- Net Income
- -$429.00 thousand
- Total Assets
- $25.34 million
- Net Cash from Operations
- -$9.65 million
Fiscal year ended Dec 31, 2025. Latest periodic SEC filing: Apr 27, 2026. Source: SEC filings (EDGAR XBRL).
Open the full financial statements for RDHL in 10KGenie
Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History